Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Trial details
- Registry ID
- NCT06463665
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as GL-ONC; GLV-1h68; Olvi-Vec
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerNCT06463665 | Genelux Corporation | Phase 2 | Recruiting | 2027-02Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |